LIPFENDRA Sparks Growth in PCSK9 Inhibitor Market Amid Rising Demand
The PCSK9 inhibitor market is experiencing rapid growth due to the approval of Merck's LIPFENDRA and the emergence of oral PCSK9 inhibitors, including AstraZeneca's AZD0780 and Aqur Biosciences' AQR-008.
Rising cases of hypercholesterolemia, dyslipidemia, and cardiovascular diseases worldwide are driving demand for effective LDL-C-lowering therapies. The need for better long-term cardiovascular risk management is supporting adoption of PCSK9-targeted treatments.
The market was valued at USD 3 billion in the 7MM in 2025, with the US accounting for the largest share. Oral PCSK9 inhibitors like LIPFENDRA offer a more convenient option for patients compared to injectable therapies. This could expand the treatment population and improve adherence.
DelveInsight's report on the PCSK9 targeted therapies market provides insights into current treatment practices, addressable patient populations, and emerging therapies. The report also forecasts the market size from 2022 to 2036, segmented by leading markets including the US, EU4 countries, UK, and Japan.